Octave

Octave has been recognized as the “Best Care Management Platform” in the 8th Annual MedTech Breakthrough award program. The recognition is a testament to our success in delivering actionable insights in a precision medicine solution for MS and our vision to redefine the standard of care for neurological diseases. Learn more:https://medtechbreakthrough.com/2024-winners/

MS Advocate Brittany Quiroz, A Hot MS is changing perceptions around life with disability. From hosting the podcast "All the Odds with A Hot MS" to initiating the ART4aCAUSE charity project, Quiroz is blazing a trail for others living with MS to “embrace their mess.” In honor of MS Awareness Month, she's extending her impact through music with the release of her first song, "Never Have My Soul," from her upcoming album, “8:28.” All proceeds will benefit the National MS Society

Read more about Brittany's MS journey and how it fuels her greater purpose:

How MS helped me find and embrace my life’s purpose For Brittany Quiroz, an MS diagnosis was an answer to years of prayer, as it helped her find her life's purpose.

We want to extend our thanks to everyone who visited the Octave team, engaged in insightful conversations, and made ACTRIMS Forum 2024 exceptional!
It was a pleasure to connect with attendees and share how Octave's Multiple Sclerosis Disease Activity ( ) Test, the first-and-only multivariate biomarker blood test is delivering actionable insights for more confident management.
Octave is proud to have had seven company and partner posters featured at the event. Check out all of Octave's posters by visiting https://www.octavebio.com/actrims-2024-post-event/

Don't miss Octave and our collaborators at the 2024 poster presentations:

1️⃣ Poster Session 1
🕕 Thursday, February 29, 6:00 - 7:30pm

2️⃣ Poster Session 2
🕕 Friday, March 1, 6:00 - 7:30pm

➡️ Visit us at Pod #631! Schedule your meeting with the Octave team and view the full list of posters: https://www.octavebio.com/actrims2024-pre-event/

Discover how Octave's Multiple Sclerosis Disease Activity (MSDA) Test, the first-and-only multivariate biomarker blood test that provides accurate measurement of multiple sclerosis (MS) disease activity, is delivering actionable insights for more confident management in clinics around the country, at 2024, February 29 – March 2!

Learn more about the science behind our Precision Care Solution at the poster presentations:

▪️ Poster Session 1
▪️ Thursday, February 29, 6:00 - 7:30pm

▪️ Poster Session 2
▪️ Friday, March 1, 6:00 - 7:30pm

➡️ Visit us at Pod #631: https://bit.ly/4bJV4bw

Octave is excited to be a part of 2024! ✈️

Join us at the ninth annual ACTRIMS event, February 29 – March 2 in West Palm Beach, Florida to learn how we are changing the paradigm of care in (MS) with our MS Solution.

➡️ Stop by Pod #631 at or schedule your meeting: https://www.octavebio.com/actrims2024-pre-event/

Thrilled to announce the launch of our dedicated patient webpage! 🌐︎

Designed with patients in mind, this comprehensive webpage provides easy access to valuable information about our multiple sclerosis (MS) Precision Care Solution.

Learn more ➡️ https://www.octavebio.com/patients/

Thrilled to announce the launch of our dedicated patient webpage! 🌐︎

Designed with patients in mind, this comprehensive webpage provides easy access to valuable information about our multiple sclerosis (MS) Precision Care Solution.

Learn more ➡️ https://www.octavebio.com/patients/

Patients - Octave Bio

Every person living with multiple sclerosis (MS) is unique and there are limited tools available that measure disease activity over time.

Octave’s Multiple Sclerosis Disease Activity (MSDA) Test enables clinicians to measure this activity through a simple blood test that gives a numeric score to measure and track disease activity over time.

Learn more about Octave’s MSDA test and the Precision Care Solution: https://www.octavebio.com/octave-msda-informational-video/

Octave MSDA Informational Video - Octave Bio

Join Olink Proteomics and Octave at PMWC - Precision Medicine World Conference to hear Ferhan Qureshi, VP of Biomarker Product Development at Octave present "Bridging Proteomics to the Clinic – A Multivariate Blood Test for Disease Activity in Multiple Sclerosis" at 9:45 a.m. PT on Thursday, Jan. 25 in the Showcase Track S2.

Learn more ➡️ https://bit.ly/480X8Jr

Attending the 42nd Annual J.P. Morgan Healthcare Conference?

Hear from Octave's Chief Commercial Officer, Maital Rasmussen, on Wednesday, Jan. 10 at 9:15 a.m. PT during the Goodwin + KPMG 5th Annual Symposium in the InterContinental Ballroom on the 5th floor for, "The New Faces of Precision Medicine: Technology, AI, and Diversity-Driven Innovation to Reality," a discussion on the strategies enabling life science companies to enhance research and development to chart new paths to success.

To schedule a meeting with Maital, please contact us at: https://bit.ly/47lwhap

🚀 Exciting News! We're delighted to announce the launch of our new Instagram page, , dedicated to sharing news, education, and most importantly the stories of the incredible individuals at the heart of our work: .

At Octave, we believe in a future where science empowers patients and their care team, and where hope and inspiration fuel the path to progress.

Join us on Instagram for exclusive content and updates as we rewrite the narrative of what it means to live with a neurodegenerative disease.

Follow the journey here: https://www.instagram.com/octavebio/

www.instagram.com

Seasons greetings and from the Octave team! ❄️

As we pause to reflect on 2023, we're filled with gratitude for our team and partners who share our commitment to advancing neurodegenerative disease care, starting with multiple sclerosis (MS).

With an estimated lifetime cost of more than $4.8 million per (MS) patient, Octave believes enabling the quadruple-aim framework alongside the use of innovative tools and solutions can positively impact patient care for neurodegenerative disease and lower overall costs. The Journal of Clinical Pathways published an article by our very own Mike Edgeworth, MD and Michael Hoffman detailing this approach.

Taking Aim at Multiple Sclerosis Mike Edgeworth, MD, and Michael Hoffman discuss how providers and payers can better collaborate by using the quadruple aim to improve the patient experience, improve health outcomes, and reduce payer cost. Engaging Payers from Journal of Clinical Pathways.

The magic of the holidays shouldn't be exclusive. However, for 3.5 million Bay Area residents, the season can be overshadowed by financial strain.

Octave is proud to continue our commitment to the community by partnering with Family Giving Tree to spread kindness by delivering specifically wished for gifts.

🎁 Join us in making a difference by donating a gift that brings joy and hope: https://wishdrive.org/octavebioscience

Octave's Multiple Sclerosis Disease Activity (MSDA) Test is in routine clinical use among clinicians as a valuable tool for managing patients with multiple sclerosis (MS), and is currently used by MS clinics around the country.

Octave Chairman of the Board and Founder shared with GenomeWeb that the MSDA Test, the first-and-only multivariate biomarker blood test, helps clinicians address "a number of clinical dilemmas throughout the entire course of this multi-decade disease," including better identification of patients at risk of disease progression and providing data that could inform whether to escalate or de-escalate therapy.

Read real-world applications of the Octave MSDA Test from leading MS experts and more ➡️ https://www.octavebio.com/news-blog/ #:~:text=Octave%C2%AEBioscience%2C%20Inc.%20Gaining%20Traction%20Among%20Clinicians%20for%20Proteomic%20Multiple%20Sclerosis%20Test%20%E2%80%93%20GeonomeWeb

Octave

Octave announces Chairman of the Board, CEO transition in preparation for accelerated commercial growth and increased patient access for its Precision Care Solution. William Hagstrom, our founder and CEO, will transition to Chairman of the Board, and Doug Biehn is appointed President and CEO.

Octave® Bioscience, Inc. Announces Chairman of the Board, CEO Transition in Preparation for Accelerated Commercial Growth and Increased Patient Access for its Precision Care Solution Octave® Bioscience, Inc., a leading precision care company that delivers a new standard for managing multiple sclerosis (MS) and other neurodegenerati

Thank you Medtech Insight for profiling Octave's work in and our $10 million grant from The Michael J. Fox Foundation for Parkinson's Research.

Octave Biosciences Takes It Up Another Semitone With Michael J Fox Foundation Grant The diagnostics company has secured $10m from the foundation to develop a biomarker test for Parkinson’s disease.

Octave enjoyed attending Personalized Medicine Coalition's annual conference to learn the latest in the practical use of precision medicine and see Board member, Michael Pellini, participate in the 'Investing in Personalized Medicine' panel.

What type of content do you find most valuable?

a) Blogs
b) Webinars
c) Podcasts
d) Videos

Comment below.

We appreciate the PharmaVoice article of "A grant from the notorious Parkinson’s foundation has sped up Octave's timeline to further advance biomarker development in the field"

https://www.pharmavoice.com/news/octave-bioscience-parkinsons-michael-j-fox/700890/
The Michael J. Fox Foundation for Parkinson's Research

LinkedIn This link will take you to a page that’s not on LinkedIn

In recognition of World Movement Disorders Day, NeurologyLive interviewed Jim Eubanks, PhD to discuss the $10 million grant awarded to Octave from The Michael J. Fox Foundation for Parkinson's Research to develop and validate a multi-analyte protein biomarker test for Parkinson’s Disease assessments.

World Movement Disorders Day: Octave’s Impact on Parkinson Disease Research Jim Eubanks, PhD, national director of medical affairs at Octave, provided thoughts on the company’s $10 million grant from The Michael J. Fox Foundation for Parkinson’s Research and highlighted the importance of awareness for movement disorders like Parkinson disease.

Octave's Chief Population Health Officer, Mike Edgeworth, sat down with Fred Goldstein and Gregg Masters, hosts of Healthcare NOW Radio, to discuss how we are changing the paradigm of multiple sclerosis (MS) care and treatment with our innovative Precision Care Solution.

🎧 Listen now: https://bit.ly/3R15tGx

PopHealth Week: Meet Mike Edgeworth MD MS Chief Population Health Officer Octave Biosciens Hosts Fred Goldstein and Gregg Masters MPH welcome Mike Edgeworth, MD, MS. Dr. Edgeworth is a neurologist and the Chief Population Health Officer at Octave Bioscience a company that is involved in cha

Delve into the inspiring journey of Octave, as our COO and Co-Founder, Melinda Thomas, joins Karen Jagoda on the Empowered Patient Radio. Together, they shed light on the challenges of multiple sclerosis (MS) care and how Octave's Solution is addressing these unmet clinical needs to improve disease management and patient outcomes.

Listen now ➡️ https://bit.ly/47yx0Wg

Empowered Patient Podcast: Blood-Based Biomarker Provides Clinical Insights About Disease Activities of MS Patients with Melinda Thomas Octave Bioscience Melinda Thomas, the COO and Co-Founder of Octave Bioscience is focused on delivering a new standard of care for multiple sclerosis and other neurodegenerative diseases.  The company aims to address the unmet needs of people living with MS using blood-based biomarkers, expanded imaging, and a cl...

We are proud to announce that Octave has been awarded a $10M grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF). The grant will be used for the discovery, development, and validation of a custom protein biomarker panel to measure Parkinson’s disease activity and progression in the clinic, helping to address a major unmet need facing the Parkinson’s community.

“MJFF is at the forefront of scientific research, and we look forward to building on their extraordinary insights as well as their deep knowledge of the disease and its pathophysiology to create the industry’s first validated multiplexed biomarker assay panel for Parkinson’s,” said William Hagstrom, Octave’s Founder and CEO. “This project is incredibly meaningful to us, as it further extends our mission to build precision care solutions that transform the lives of people living with high-cost, complex, and debilitating neurodegenerative conditions. We’re excited to apply our experience and learnings from Multiple Sclerosis to Parkinson’s, and help change the treatment paradigm for people living with this disease.”

Read more ➡️ https://www.octavebio.com/news-blog/ #:~:text=Nov%2015th%2C%202023,Read%20More

We are ecstatic to share Octave has won the “MedTech Solution of the Year” from BioTech Breakthrough Awards! 🏆

This honor highlights our commitment to changing the paradigm of care delivering objective insights that can lead to better management of neurodegenerative diseases.

Thank you to our incredible team, partners, and community for making this possible. Together, we’re changing the narrative around management!

Learn more ➡️ https://biotechbreakthroughawards.com/2023-winners/ #:~:text=MedTech%20Solution%20of%20the%20Year

2023 Winners - BioTech Breakthrough Awards

We extend our heartfelt support to the participants of the Challenge Walk MS: Southern California, where strength and resilience meet the road ahead! 👟🌊

Octave is proud to sponsor this year's event, and we're honored to stand with the National Multiple Sclerosis Society, and those taking on 50 miles in 3 days to help create a world free of multiple sclerosis (MS). 🌎

Learn more: https://events.nationalmssociety.org/index.cfm?fuseaction=donorDrive.event&eventID=1560&language=en

I'm supporting the National MS Society! The National MS Society's vision is a world free of MS. The Society mobilizes people and resources so that everyone affected by MS can live their best lives as we stop MS in its tracks, restore what has been lost and end MS forever.

We were thrilled to present nine posters featuring our MS Precision Care Solution at ! We are grateful for the opportunity to connect with so many leaders in sclerosis (MS) care and participate in a and a product theater. This event helped reaffirm the value of our MS Precision Care Solution for patients and their physicians as we work toward helping patients with MS live more harmonious lives. Read more in our blog: https://www.octavebio.com/news-blog/

At , Octavesponsored a product theater on Precision Medicine, featuring innovations to tailor care for people living with . We were delighted to have Dr. Barry Singer, Director of the MS Center for Innovations in Care, participate in the event! NeurologyLive sat down with Dr. Singer to learn more about his perspectives on how biomarker tests, like Octave’s MSDA Blood Test, can help shape a patient’s treatment plan and his thoughts on other topics that piqued his interest at MSMilan2023.

Check out the interview here:

NeuroVoices: Barry Singer, MD, on Recent Strides in the Treatment and Management of Multiple Sclerosis The director and founder of The MS Center for Innovations in Care provided perspective on some of the significant strides made in recent years to improve the care and access to affordable treatments for patients with multiple sclerosis.

At Octave we’re proud to support the next generation of (MS) researchers and clinical specialists! The ACTRIMS Young Scientist Summit in Clinical Neuroimmunology kicks off today, giving students, neurology residents, postdoctoral fellows and junior faculty the opportunity to share their work, connect with colleagues, and learn more about advances in MS research and treatment.

Young Scientist Summit Didactic Webinar